Related Parties Transactions (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 08, 2020 |
Jul. 10, 2019 |
Jun. 30, 2022 |
Jan. 31, 2022 |
Oct. 31, 2020 |
Jul. 19, 2017 |
Feb. 24, 2015 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Dec. 31, 2021 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 01, 2021 |
Sep. 07, 2021 |
Jul. 01, 2021 |
Jul. 01, 2020 |
Feb. 27, 2019 |
|
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Current amount | $ 500,000 | $ 500,000 | $ 0 | ||||||||||||||||
Non-current amount | 1,480 | $ 1,480 | |||||||||||||||||
Interest rate | 6.50% | ||||||||||||||||||
Discount of stock price | 70.00% | 12.00% | |||||||||||||||||
Outstanding loan amount | $ 501,480 | 33,520 | |||||||||||||||||
Convertible loan | $ 500,000 | ||||||||||||||||||
Principal amount | $ 1,000,000 | ||||||||||||||||||
Bears interest | 5.00% | ||||||||||||||||||
Working capital percentage | 6.40% | ||||||||||||||||||
Conversion price description | The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided. | ||||||||||||||||||
Consultant services agreement | 0 | $ 0 | 1,889 | ||||||||||||||||
Maturity date | Jul. 18, 2019 | Nov. 30, 2022 | |||||||||||||||||
Loan agreement total amount | $ 507,000 | ||||||||||||||||||
Loan agreement, description | The advances bear interest rate of 12% per annum. | ||||||||||||||||||
Due amount | 0 | $ 0 | 124,972 | ||||||||||||||||
Accrued interest | 40,878 | 40,878 | 40,878 | ||||||||||||||||
Outstanding principal and accrued interest | 146,790 | 146,790 | 168,131 | ||||||||||||||||
Interest expenses | $ 5,208 | $ 5,679 | $ 15,922 | $ 16,670 | |||||||||||||||
BioFirst (Australia) [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Due from rgene amounted | $ 250,000 | $ 67,873 | $ 361,487 | ||||||||||||||||
Interest rate percentage | 6.50% | 6.50% | |||||||||||||||||
Loan settled amount | $ 249,975 | ||||||||||||||||||
Ownership percentage | 6.50% | 6.50% | |||||||||||||||||
Accrued interest | $ 1,038,775 | ||||||||||||||||||
Research fee | 491,816 | ||||||||||||||||||
Aggregate working capital | $ 211,147 | $ 132,443 | |||||||||||||||||
LBG USA, Inc.[Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Ownership percentage | 0.00% | ||||||||||||||||||
AsiaGene [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Ownership percentage | 0.00% | 0.00% | 0.00% | ||||||||||||||||
YuanGene [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Ownership percentage | 0.00% | 0.00% | 0.00% | ||||||||||||||||
Jiangs [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Ownership percentage | 0.00% | 0.00% | 1.00% | ||||||||||||||||
Rgene [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Non-current amount | $ 49,110 | $ 49,110 | |||||||||||||||||
Interest rate | 1.00% | 1.00% | |||||||||||||||||
BHK Co Development Agreement [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Loan agreement, description | The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. | ||||||||||||||||||
LBG USA, Inc.[Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Outstanding advance | $ 675 | $ 675 | $ 0 | ||||||||||||||||
BioLite Japan [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Loan agreement, description | Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan’s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate. | ||||||||||||||||||
Outstanding advance | 150,000 | 150,000 | 150,000 | ||||||||||||||||
Keypoint [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Loan agreement, description | Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. | ||||||||||||||||||
Balance of outstanding loans | 1,610 | 0 | |||||||||||||||||
BioFirst [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Loan agreement, description | The advances bear interest 1% per month (or equivalent to 12% per annum). | ||||||||||||||||||
AsiaGene [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Aggregate working capital | 24,017 | 24,017 | |||||||||||||||||
YuanGene [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Aggregate working capital | 9,205 | 9,205 | |||||||||||||||||
Jiangs [Member] | |||||||||||||||||||
Related Parties Transactions (Details) [Line Items] | |||||||||||||||||||
Outstanding advance | $ 19,789 | $ 19,789 | $ 18,750 |